Recombinant CTLA-4 Extracellular Domain & Fc fragment (human IgG1 isotype) Protein
Product Sizes
1 mg
£746.00
YR0045-1MG
5 mg
£1442.00
YR0045-5MG
20 mg
£2835.00
YR0045-20MG
About this Product
- SKU:
- YR0045
- Additional Names:
- ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12
- Application:
- Cell-based/Functional Assay
- Extra Details:
- Abatacept (trade name Orencia, Bristol-Myers-Squibb), a fusion protein of a Fc fragment (human IgG1 isotype) and the extracellular domain of CTLA-4, can be used to extend graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. Abatacept binds to CD80 (B7-1) with more avidity than to CD86 (B7-2). Abatacept inhibits the costimulation of T cells. Abatacept differs from belatacept (trade name Nulojix) by only 2 amino acids.The CTLA-4 protein is important for T-cell costimulation and selectively blocks the process of T-cell activation.
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Immunogen:
- CTLA-4
- Isotype:
- IgG1
- Purity:
- >95%
- Shipping Conditions:
- Blue Ice
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- ABclonal Technology
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Recombinant Proteins
- Manufacturer's Data Sheet:YR0045
